The drug has been specifically recommended for NHS use alongside Genentech’s Avastin (bevacizumab) as a maintenance treatment in adults with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer, whose disease is associated with homologous recombination deficiency (HRD)-positive status.
Eligible patients will also need to be in complete or partial response to first-line platinum-based chemotherapy…
